Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA® in Advanced Metastatic Melanoma and Head and Neck Cancer

NEXT STORY
US & EU Direct-to-consumer Genetic Testing Market Report 2021
PREV STORY
COVID-19 Treatment Clinical Landscape Market Report 2021: Outlook for Therapeutics is Expected to Decline Progressively Throughout 2021 Due to Global Vaccination Programs
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKT Cells in Neuroblastoma at ASGCT Annual Meeting

author_avatar
NASDAQ Market News

UroGen Pharma to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 15, 2018

Conference Call and Webcast Scheduled for 8:30 AM ET RA’ANANA, Israel and NEW YORK, March ...

author_avatar
NASDAQ Market News

BriaCell Provides Clinical Update on its Lead Immunotherapy Drug in Advanced Breast Cancer

BERKELEY, Calif. and VANCOUVER, British Columbia, Jan. 03, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics ...

author_avatar
NASDAQ Market News